MIMETAS, in a consortium with Maastricht University (MERLN), KU Leuven, Xplore Instruments, LUMC, Tenco DDM, DSM R&D Solutions and IMEC, has received 4.3 million EUR funding for development of a platform for high-throughput testing of biomaterials in a physiologically relevant environment on-a-chip.
The objective of the iPlacenta project is to develop state-of-the-art models to mimic the placenta in vitro. This Huffington Post article stresses the importance of modeling what is probably the most important organ in the human body, giving life to us all.
MIMETAS, the market leader in Organ-on-a-chip products, announced that the National Cancer Institute recently awarded them a phase 1 SBIR grant totally $300,000 to develop personalized prostate cancer-on-a-chip models that can more accurately reproduce the tumor micro-environment.
In this paper, we investigate the feasibility of adapting OrganoPlate® technology for therapy selection for breast cancer. The work is a collaboration with Prof. Richard Weinschilbaum and Dr. Liewei Wang from the Mayo Clinic in Minnesota.
Karlijn Wilschut, Senior Scientist at Mimetas and Oksana Sirenko, Research Scientist at Molecular Devices wrote this application note on a quantitative, confocal high-content imaging method, enabling high-throughput phenotypic assessment of treatment effects upon the viability and morphology of 3D neuronal cultures in OrganoPlate®.